GlassScriptPhysician profile
Sreenath Kodali
NPI 1376823567
$2,884.24
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,411 · 2020: $350 · 2021: $85.49 · 2023: $22.71 · 2024: $15.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.71 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.71 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Pfizer INC. | $262.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.94 | 2019 | |
| Astellas Pharma US INC | $220.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $194.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $152.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $140.69 | 2019 | |
| Genentech USA, INC. | $125.01 | 2019 | |
| Incyte Corporation | $118.56 | 2019 | |
| Tesaro, INC. | $109.64 | 2019 | |
| Puma Biotechnology, INC. | $101.83 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $90.20 | 2019-2021 | |
| Janssen Biotech, INC. | $80.68 | 2019 | |
| Amgen INC. | $78.55 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.67 | 2019 | |
| Lilly USA, LLC | $43.10 | 2019 | |
| Taiho Oncology, INC. | $38.54 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $38.48 | 2019 | |
| Celgene Corporation | $37.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.63 | 2019 | |
| Abbvie INC. | $23.61 | 2019 | |
| Eisai INC. | $22.81 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.71 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.06 | 2019 | |
| Clovis Oncology, INC. | $17.71 | 2019 | |
| Aveo Pharmaceuticals, INC. | $15.00 | 2024 | |
| Verastem, INC. | $14.53 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreenath Kodali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.